// Auto-generated - do not edit
export const substanceName = "Propranolol";
export const sources = [{"id":"drugbank","fileName":"DRUGBANK - Propranolol.md","displayName":"DrugBank","size":26358},{"id":"protestkit","fileName":"PROTESTKIT - Propranolol.json","displayName":"Protest Kit","size":1420},{"id":"tripsit-factsheets","fileName":"TRIPSIT_FACTSHEETS - Propranolol.md","displayName":"TripSit Factsheets","size":540},{"id":"wikipedia","fileName":"WIKIPEDIA - Propranolol.md","displayName":"Wikipedia","size":22257}];
export const contents: Record<string, string> = {
  "drugbank": `# Propranolol
*Source: https://go.drugbank.com/drugs/DB00571*

## Overview

### Description

This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.

### Background

Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors.
9
Propranolol is used to treat a number of conditions but most commonly is used for hypertension.
8
,
9
,
10
Propranolol was granted FDA approval on 13 November 1967.
9

### Indication

Propranolol is indicated to treat hypertension.
10
,
9
Propranolol is also indicated to treat angina pectoris due to coronary atherosclerosis, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, pheochromocytoma, and proliferating infantile hemangioma.
9
,
10

### Pharmacodynamics

Propranolol is a beta-adrenergic receptor antagonist used to treat hypertension.
9
,
10
Propranolol has a long duration of action as it is given once or twice daily depending on the indication.
8
,
9
,
10
When patients abruptly stop taking propranolol, they may experience exacerbations of angina and myocardial infarctions.
10

### Mechanism of Action

Beta-1 adrenergic receptor
Antagonist

### Absorption

Patients taking doses of 40mg, 80mg, 160mg, and 320mg daily experienced C
max
values of 18±15ng/mL, 52±51ng/mL, 121±98ng/mL, and 245±110ng/mL respectively.
4
Propranolol has a T
max
of approximately 2 hours, though this can range from 1 to 4 hours in fasting patients.
5
Taking propranolol with food does not increase T
max
but does increase bioavailability.
5

### Metabolism

Propranolol undergoes side chain oxidation to α-naphthoxylactic acid, ring oxidation to 4’-hydroxypropranolol, or glucuronidation to propranolol glucuronide.
7
It can also be N-desisopropylated to become N-desisopropyl propranolol.
1
17% of a dose undergoes glucuronidation and 42% undergoes ring oxidation.
6
Hover over products below to view reaction partners
Propranolol
N-desisopropylpropranolol
4'-hydroxypropanolol
Propranolol Glucuronide
α-Naphthoxylactic Acid

### Half-life

The elimination half-life of propranolol is approximately 8 hours.
10
The plasma half-life of propranolol is 3 to 6 hours.
8
,
9

### Toxicity

Symptoms of overdose include hypotension, hypoglycemic seizure, restlessness, euphoria, insomnia.
8
Patients with asthma may develop bronchospasm.
8
In case of overdose, monitor vital signs, mental status, and blood glucose.
8
Treat hypotension with intravenous fluids, bradycardia with atropine, and isoproterenol and aminophylline for bronchospasm.
8
If patients do not respond to intravenous fluids, follow up with glucagon 50-150µg/kg intravenously, then 1-5mg/hour, followed by catecholamines.
8
,
9
,
10
Dialysis will not be useful as propranolol is highly protein bound.
8
,
9
,
10

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Abacavir
Propranolol may decrease the excretion rate of Abacavir which could result in a higher serum level.
Abaloparatide
The risk or severity of adverse effects can be increased when Propranolol is combined with Abaloparatide.
Abametapir
The serum concentration of Propranolol can be increased when it is combined with Abametapir.
Abatacept
The metabolism of Propranolol can be increased when combined with Abatacept.
Abiraterone
The serum concentration of Propranolol can be increased when it is combined with Abiraterone.

### Food Interactions

Avoid alcohol. Alcohol increases propranolol plasma concentrations.
Avoid natural licorice. Natural licorice inhibits the metabolism of propranolol, increasing drug exposure.
Take with food.

## Chemical Information

**DrugBank ID:** DB00571

**Synonyms:** 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol
1-[(1-Methylethyl)amino]-3-(1-naphthalenyloxy)-2-propanol
beta-Propranolol
Propanalol
Propanolol
Propranolol
Propranololo
Propranololum
β-Propranolol

**Chemical Formula:** C
16
H
21
NO
2

**SMILES:** CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2

**Weight:** Average: 259.3434
Monoisotopic: 259.157228921

**IUPAC Name:** 1-(naphthalen-1-yloxy)-3-[(propan-2-yl)amino]propan-2-ol

## Additional Information

### Modality

Small Molecule

### Patents

Patent Number
Pediatric Extension
Expires (estimated)
Region
US6500454
No
2002-12-31
2021-10-04
US
US8338489
No
2012-12-25
2028-10-16
US
US8987262
No
2015-03-24
2028-10-16
US

### Indicated Conditions

22

### Phase 0

7

### Phase 1

65

### Phase 2

135

### Phase 3

59

### Phase 4

64

### Therapeutic Categories

Adrenergic
beta-Antagonists
Antihypertensive Agents Indicated for
Hypertension

### Summary

Propranolol
is a non-selective beta adrenergic antagonist used to treat hypertension, angina, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, and pheochromocytoma.

### Brand Names

Hemangeol, Hemangiol, Inderal, Innopran

### Generic Name

Propranolol

### DrugBank Accession Number

DB00571

### Groups

Approved, Investigational

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Propranolol (DB00571)
×
Close

### External IDs

AY 20694
AY-20694

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Management of
Akathisia caused by antipsychotic use
••• •••••
Create Account
Management of
Angina pectoris
••••••••••••
Create Account
••••••
Management of
Angina pectoris
••••••••••••
Create Account
Management of
Anxiety
••••••••••••
Create Account
Management of
Atrial fibrillation
••••••••••••
Create Account
••••• ••••••••••• ••••••••
Create Account

### Mechanism of action

Propranolol is a nonselective β-adrenergic receptor antagonist.
2
Blocking of these receptors leads to vasoconstriction, inhibition of angiogenic factors like vascular endothelial growth factor (VEGF) and basic growth factor of fibroblasts (bFGF), induction of apoptosis of endothelial cells, as well as down regulation of the renin-angiotensin-aldosterone system.
2
Target
Actions
Organism
A
Beta-1 adrenergic receptor
antagonist
Humans
U
Beta-2 adrenergic receptor
antagonist
Humans
U
Beta-3 adrenergic receptor
antagonist
Humans
U
5-hydroxytryptamine receptor 1A
other/unknown
Humans
U
5-hydroxytryptamine receptor 1B
other/unknown
Humans

### Volume of distribution

The volume of distribution of propranolol is approximately 4L/kg
8
,
9
or 320L.
4

### Protein binding

Approximately 90% of propranolol is protein bound in plasma.
8
,
9
,
10
Other studies have reported ranges of 85-96%.
5

### Route of elimination

91% of an oral dose of propranolol is recovered as 12 metabolites in the urine.
6

### Clearance

The clearance of propranolol is 2.7±0.03L/h/kg in infants <90 days and 3.3±0.35L/h/kg in infants >90 days.
8
Propranolol clearance increases linearly with hepatic blood flow.
3
Propranolol has a clearance in hypertensive adults of 810mL/min.
4

### Pathways

Pathway
Category
Propranolol Action Pathway
Drug action

### Product Ingredients

Ingredient
UNII
CAS
InChI Key
Propranolol hydrochloride
F8A3652H1V
318-98-9
ZMRUPTIKESYGQW-UHFFFAOYSA-N

### Product Images

Previous
Next

### International/Other Brands

Angilol
/
AVLOCARDYL
/
Bedranol SR
/
Cardinol
/
Ciplar
/
Deralin
/
Dociton
/
Duranol
/
Inderal
/
Indobloc
/
INNOPRAN
/
Prophylux
/
Sumial

### Brand Name Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Detensol Tab 10mg
Tablet
10 mg
Oral
Desbergers LtÉe, Division Of Technilab Inc.
1980-12-31
1999-09-17
Canada
Detensol Tab 120mg
Tablet
120 mg
Oral
Desbergers LtÉe, Division Of Technilab Inc.
1981-12-31
1999-09-17
Canada
Detensol Tab 40mg
Tablet
40 mg
Oral
Desbergers LtÉe, Division Of Technilab Inc.
1980-12-31
1999-09-17
Canada
Detensol Tab 80mg
Tablet
80 mg
Oral
Desbergers LtÉe, Division Of Technilab Inc.
1980-12-31
1999-09-17
Canada
Hemangeol
Solution
4.28 mg/1mL
Oral
Pierre Fabre Pharma S.R.L.
2014-04-14
Not applicable
US

### Generic Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Apo-propranolol
Tablet
80 mg
Oral
Apotex Corporation
1980-12-31
Not applicable
Canada
Apo-propranolol
Tablet
120 mg
Oral
Apotex Corporation
1981-12-31
Not applicable
Canada
Apo-propranolol
Tablet
40 mg
Oral
Apotex Corporation
1980-12-31
Not applicable
Canada
Apo-propranolol
Tablet
20 mg
Oral
Apotex Corporation
1986-12-31
Not applicable
Canada
Apo-propranolol
Tablet
10 mg
Oral
Apotex Corporation
1980-12-31
Not applicable
Canada

### Mixture Products

Name
Ingredients
Dosage
Route
Labeller
Marketing Start
Marketing End
Region
Image
DOCITEREN
Propranolol hydrochloride
(80 mg/1)
+
Hydrochlorothiazide
(12.5 mg/1)
+
Triamterene
(25 mg/1)
Tablet
Oral
2006-07-01
Not applicable
Germany
Inderide
Propranolol hydrochloride
(80 mg/1)
+
Hydrochlorothiazide
(25 mg/1)
Tablet
Oral
Wyeth Pharmaceuticals Inc.
1979-07-01
2008-09-30
US
Inderide
Propranolol hydrochloride
(40 mg/1)
+
Hydrochlorothiazide
(25 mg/1)
Tablet
Oral
Wyeth Pharmaceuticals Inc.
1979-07-01
2008-09-30
US
Inderide-40 Tab
Propranolol hydrochloride
(40 mg)
+
Hydrochlorothiazide
(25 mg)
Tablet
Oral
Wyeth Ayerst Canada Inc.
1993-12-31
2001-06-05
Canada
Inderide-80 Tab
Propranolol hydrochloride
(80 mg)
+
Hydrochlorothiazide
(25 mg)
Tablet
Oral
Wyeth Ayerst Canada Inc.
1993-12-31
2001-05-22
Canada

### Unapproved/Other Products

Name
Ingredients
Dosage
Route
Labeller
Marketing Start
Marketing End
Region
Image
Propranolol Scopolamine
Propranolol hydrochloride
(20 mg/20.25mg)
+
Scopolamine
(.25 mg/20.25mg)
Tablet
Oral
TPS
2014-10-01
Not applicable
US
Propranolol Scopolamine
Propranolol hydrochloride
(40 mg/40.5mg)
+
Scopolamine
(.5 mg/40.5mg)
Tablet
Oral
TPS
2014-10-01
Not applicable
US

### ATC Codes

C07FX01 — Propranolol and other combinations
C07FX — Beta blocking agents, other combinations
C07F — BETA BLOCKING AGENTS, OTHER COMBINATIONS
C07 — BETA BLOCKING AGENTS
C — CARDIOVASCULAR SYSTEM
C07AA05 — Propranolol
C07AA — Beta blocking agents, non-selective
C07A — BETA BLOCKING AGENTS
C07 — BETA BLOCKING AGENTS
C — CARDIOVASCULAR SYSTEM
C07BA05 — Propranolol and thiazides
C07BA — Beta blocking agents, non-selective, and thiazides
C07B — BETA BLOCKING AGENTS AND THIAZIDES
C07 — BETA BLOCKING AGENTS
C — CARDIOVASCULAR SYSTEM

### Drug Categories

Adrenergic Agents
Adrenergic Antagonists
Adrenergic beta-Antagonists
Agents causing hyperkalemia
Alcohols
Amines
Amino Alcohols
Antiarrhythmic agents
Antihypertensive Agents
Antihypertensive Agents Indicated for Hypertension
Beta Blocking Agents and Thiazides
Beta Blocking Agents, Non-Selective
Beta Blocking Agents, Non-Selective, and Thiazides
Bradycardia-Causing Agents
Cardiovascular Agents
Cytochrome P-450 CYP1A2 Substrates
Cytochrome P-450 CYP2C19 Substrates
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 CYP2D6 Inhibitors (weak)
Cytochrome P-450 CYP2D6 Substrates
Cytochrome P-450 CYP3A Substrates
Cytochrome P-450 CYP3A4 Substrates
Cytochrome P-450 CYP3A5 Substrates
Cytochrome P-450 CYP3A7 Substrates
Cytochrome P-450 Enzyme Inhibitors
Cytochrome P-450 Substrates
Drugs that are Mainly Renally Excreted
Hypotensive Agents
Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates
Naphthalenes
Negative Inotrope
Neurotransmitter Agents
OCT2 Inhibitors
P-glycoprotein inhibitors
P-glycoprotein substrates
Phenoxypropanolamines
Propanolamines
Propanols
QTc Prolonging Agents
Vasodilating Agents

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Naphthalenes
Sub Class
Not Available
Direct Parent
Naphthalenes
Alternative Parents
Alkyl aryl ethers
/
Secondary alcohols
/
1,2-aminoalcohols
/
Dialkylamines
/
Organopnictogen compounds
/
Hydrocarbon derivatives
Substituents
1,2-aminoalcohol
/
Alcohol
/
Alkyl aryl ether
/
Amine
/
Aromatic homopolycyclic compound
/
Ether
/
Hydrocarbon derivative
/
Naphthalene
/
Organic nitrogen compound
/
Organic oxygen compound
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
secondary amine, propanolamine, naphthalenes (
CHEBI:8499
)

### Kingdom

Organic compounds

### Super Class

Benzenoids

### Class

Naphthalenes

### Direct Parent

Naphthalenes

### Alternative Parents

Alkyl aryl ethers
/
Secondary alcohols
/
1,2-aminoalcohols
/
Dialkylamines
/
Organopnictogen compounds
/
Hydrocarbon derivatives

### Substituents

1,2-aminoalcohol
/
Alcohol
/
Alkyl aryl ether
/
Amine
/
Aromatic homopolycyclic compound
/
Ether
/
Hydrocarbon derivative
/
Naphthalene
/
Organic nitrogen compound
/
Organic oxygen compound

### Molecular Framework

Aromatic homopolycyclic compounds

### External Descriptors

secondary amine, propanolamine, naphthalenes (
CHEBI:8499
)

### Affected organisms

Humans

### UNII

9Y8NXQ24VQ

### CAS number

525-66-6

### InChI Key

AQHHHDLHHXJYJD-UHFFFAOYSA-N

### InChI

InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3

### Synthesis Reference

US3520919

### General References

Harrison PM, Tonkin AM, Cahill CM, McLean AJ: Rapid and simultaneous extraction of propranolol, its neutral and basic metabolites from plasma and assay by high-performance liquid chromatography. J Chromatogr. 1985 Oct 11;343(2):349-58. [
Article
]
Hagen R, Ghareeb E, Jalali O, Zinn Z: Infantile hemangiomas: what have we learned from propranolol? Curr Opin Pediatr. 2018 Aug;30(4):499-504. doi: 10.1097/MOP.0000000000000650. [
Article
]
Weiss YA, Safar ME, Lehner JP, Levenson JA, Simon A, Alexandre JM: (+)-Propranolol clearance, an estimation of hepatic blood flow in man. Br J Clin Pharmacol. 1978 May;5(5):457-60. doi: 10.1111/j.1365-2125.1978.tb01655.x. [
Article
]
Chidsey CA, Morselli P, Bianchetti G, Morganti A, Leonetti G, Zanchetti A: Studies of the absorption and removal of propranolol in hypertensive patients during therapy. Circulation. 1975 Aug;52(2):313-8. doi: 10.1161/01.cir.52.2.313. [
Article
]
Routledge PA, Shand DG: Clinical pharmacokinetics of propranolol. Clin Pharmacokinet. 1979 Mar-Apr;4(2):73-90. doi: 10.2165/00003088-197904020-00001. [
Article
]
Walle T, Walle UK, Olanoff LS: Quantitative account of propranolol metabolism in urine of normal man. Drug Metab Dispos. 1985 Mar-Apr;13(2):204-9. [
Article
]
Walle T, Walle K, Mathur RS, Palesch YY, Conradi EC: Propranolol metabolism in normal subjects: association with sex steroid hormones. Clin Pharmacol Ther. 1994 Aug;56(2):127-32. [
Article
]
FDA Approved Drug Products: HEMANGEOL (propranolol hydrochloride) oral solution [
Link
]
FDA Approved Drug Products: Propranolol Oral Tablet [
Link
]
FDA Approved Drug Products: INNOPRAN XL (propranolol hydrochloride) extended release capsules [
Link
]
FDA Approved Drug Products: INDERIDE (propranolol hydrochloride and hydrochlorothiazide) tablets [
Link
]

### External Links

Human Metabolome Database
HMDB0001849
KEGG Drug
D08443
KEGG Compound
C07407
PubChem Compound
4946
PubChem Substance
46505387
ChemSpider
4777
BindingDB
25761
RxNav
8787
ChEBI
8499
ChEMBL
CHEMBL27
Therapeutic Targets Database
DAP000089
PharmGKB
PA451145
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Propranolol

### Human Metabolome Database

HMDB0001849

### KEGG Drug

D08443

### KEGG Compound

C07407

### PubChem Compound

4946

### PubChem Substance

46505387

### ChemSpider

4777

### BindingDB

25761

### RxNav

8787

### ChEBI

8499

### ChEMBL

CHEMBL27

### Therapeutic Targets Database

DAP000089

### PharmGKB

PA451145

### Guide to Pharmacology

GtP Drug Page

### RxList

RxList Drug Page

### Drugs.com

Drugs.com Drug Page

### Wikipedia

Propranolol

### FDA label

Download
(256 KB)

### MSDS

Download
(74.7 KB)

### Manufacturers

Akrimax pharmaceuticals llc
Glaxosmithkline llc
Actavis elizabeth llc
Inwood laboratories inc sub forest laboratories inc
Mylan pharmaceuticals inc
Par pharmaceutical
Upsher smith laboratories inc
Roxane laboratories inc
App pharmaceuticals llc
Baxter healthcare corp anesthesia critical care
Bedford laboratories div ben venue laboratories inc
Hikma farmaceutica (portugal) sa
Sandoz canada inc
Smith and nephew solopak div smith and nephew
Solopak medical products inc
Morton grove pharmaceuticals inc
Wyeth ayerst laboratories
Clonmel healthcare ltd
Duramed pharmaceuticals inc sub barr laboratories inc
Interpharm inc
Ipca laboratories ltd
Ivax pharmaceuticals inc sub teva pharmaceuticals usa
Lederle laboratories div american cyanamid co
Mutual pharmaceutical co inc
Northstar healthcare holdings ltd
Par pharmaceutical inc
Pliva inc
Purepac pharmaceutical co
Sandoz inc
Schering corp sub schering plough corp
Superpharm corp
Teva pharmaceuticals usa inc
Vintage pharmaceuticals
Warner chilcott div warner lambert co
Warner chilcott inc
Watson laboratories inc

### Packagers

Actavis Group
Advanced Pharmaceutical Services Inc.
Akrimax Pharmaceuticals
Amerisource Health Services Corp.
Apotheca Inc.
APP Pharmaceuticals
A-S Medication Solutions LLC
Barr Pharmaceuticals
Baxter International Inc.
Bedford Labs
Ben Venue Laboratories Inc.
Bryant Ranch Prepack
Cardinal Health
Caremark LLC
Comprehensive Consultant Services Inc.
Dept Health Central Pharmacy
Direct Dispensing Inc.
Dispensing Solutions
Diversified Healthcare Services Inc.
Eurand Pharmaceuticals Inc.
General Injectables and Vaccines Inc.
GlaxoSmithKline Inc.
Group Health Cooperative
H and H Laboratories
H.J. Harkins Co. Inc.
Heartland Repack Services LLC
Heritage Pharmaceuticals
Hikma Pharmaceuticals
Ipca Laboratories Ltd.
Ivax Pharmaceuticals
Kaiser Foundation Hospital
Lake Erie Medical and Surgical Supply
Liberty Pharmaceuticals
Major Pharmaceuticals
Medisca Inc.
Murfreesboro Pharmaceutical Nursing Supply
Mylan
Northstar Rx LLC
Nucare Pharmaceuticals Inc.
Palmetto Pharmaceuticals Inc.
Par Pharmaceuticals
PCA LLC
PD-Rx Pharmaceuticals Inc.
Pharmaceutical Utilization Management Program VA Inc.
Pharmacy Service Center
Pharmedix
Physicians Total Care Inc.
Piramal Healthcare
Pliva Inc.
Preferred Pharmaceuticals Inc.
Prepackage Specialists
Prepak Systems Inc.
Qualitest
Rebel Distributors Corp.
Remedy Repack
Resource Optimization and Innovation LLC
Rouses Point Pharmaceuticals LLC
Roxane Labs
Sandhills Packaging Inc.
Sandoz
Southwood Pharmaceuticals
Stat Rx Usa
Tya Pharmaceuticals
UDL Laboratories
United Research Laboratories Inc.
Upsher Smith Laboratories
Vangard Labs Inc.
Watson Pharmaceuticals
West-Ward Pharmaceuticals
Wyeth Pharmaceuticals

### Dosage Forms

Form
Route
Strength
Tablet, film coated
Oral
10 mg/1
Tablet, film coated
Oral
40 mg/1
Tablet, film coated
Oral
80 mg/1
Tablet, film coated
Oral
80 MG
Tablet, film coated
Oral
Solution
Oral
4.28 mg/1mL
Solution
Oral
3.75 MG/ML
Solution
Oral
3.75 mg / mL
Solution
Oral
375.000 mg
Injection, solution
Intravenous
5 MG/5ML
Liquid
Intravenous
1 mg / mL
Capsule, extended release
Oral
120 mg
Capsule, extended release
Oral
160 mg
Capsule, extended release
Oral
60 mg
Capsule, extended release
Oral
80 mg
Tablet
Oral
10.000 mg
Tablet
Oral
Capsule, extended release
Oral
120 mg/1
Capsule, extended release
Oral
80 mg/1
Tablet
Oral
40.0 mg
Tablet
Oral
Tablet
Oral
10.00 mg
Tablet
Oral
80 mg
Tablet
Oral
120 mg
Tablet
Oral
100 MG
Tablet
Oral
25 MG
Tablet
Oral
40.000 mg
Injection, solution
Intravenous
1 mg/mL
Tablet, film coated
Oral
Capsule, gelatin coated
Oral
120 mg/1
Capsule, gelatin coated
Oral
160 mg/1
Capsule, gelatin coated
Oral
60 mg/1
Capsule, gelatin coated
Oral
80 mg/1
Injection
Intravenous
1 mg/1mL
Injection, solution
Intravenous
1 mg/1mL
Solution
Oral
20 mg/5mL
Solution
Oral
40 mg/5mL
Tablet
Oral
10 mg/1
Tablet
Oral
20 mg/1
Tablet
Oral
40 mg/1
Tablet
Oral
50 mg/1
Tablet
Oral
60 mg/1
Tablet
Oral
80 mg/1
Capsule, extended release
Oral
160 mg/1
Capsule, extended release
Oral
60 mg/1
Solution
Intravenous
1 mg / mL
Tablet
Oral
10 mg/301
Tablet
Oral
20 mg
Tablet, film coated
Oral
40 mg
Tablet
Oral
40 mg
Tablet
Oral
10 mg
Tablet, film coated
Oral
10 mg
Tablet, coated
Oral
10 mg
Tablet, coated
Oral
40 mg

### Prices

Unit description
Cost
Unit
Propranolol hcl powder
11.63USD
g
Propranolol 1 mg/ml vial
10.0USD
ml
Inderal la 160 mg capsule
8.41USD
capsule
Inderal LA 160 mg 24 Hour Capsule
7.6USD
capsule
Inderal la 160 mg capsule sa
7.01USD
capsule
Inderal la 120 mg capsule
6.42USD
capsule
Inderal LA 120 mg 24 Hour Capsule
5.8USD
capsule
Inderal la 120 mg capsule sa
5.36USD
capsule
Inderal la 80 mg capsule
5.18USD
capsule
Inderal LA 60 mg 24 Hour Capsule
4.79USD
capsule
Inderal LA 80 mg 24 Hour Capsule
4.68USD
capsule
Inderal la 60 mg capsule
4.43USD
capsule
Inderal la 80 mg capsule sa
4.32USD
capsule
Inderal la 60 mg capsule sa
3.7USD
capsule
Propranolol HCl CR 160 mg 24 Hour Capsule
2.62USD
capsule
InnoPran XL 80 mg 24 Hour Capsule
2.5USD
capsule
InnoPran XL 120 mg 24 Hour Capsule
2.46USD
capsule
Innopran xl 120 mg capsule
2.41USD
capsule
Innopran xl 80 mg capsule
2.41USD
capsule
Inderide 80-25 mg tablet
2.17USD
tablet
Propranolol HCl CR 120 mg 24 Hour Capsule
2.0USD
capsule
Inderide 40-25 mg tablet
1.74USD
tablet
Propranolol HCl CR 80 mg 24 Hour Capsule
1.61USD
capsule
Propranolol HCl CR 60 mg 24 Hour Capsule
1.38USD
capsule
Propranolol HCl 60 mg tablet
1.27USD
tablet
Inderal-La 160 mg Sustained-Release Capsule
1.26USD
capsule
Inderal-La 120 mg Sustained-Release Capsule
1.07USD
capsule
Inderal-La 80 mg Sustained-Release Capsule
0.69USD
capsule
Propranolol HCl 80 mg tablet
0.66USD
tablet
Propranolol-HCTZ 80-25 mg tablet
0.65USD
tablet
Inderal-La 60 mg Sustained-Release Capsule
0.62USD
capsule
Propranolol-HCTZ 40-25 mg tablet
0.61USD
tablet
Propranolol 80 mg tablet
0.58USD
tablet
Propranolol 60 mg tablet
0.56USD
tablet
Propranolol HCl 40 mg tablet
0.53USD
tablet
Propranolol 40 mg tablet
0.45USD
tablet
Propranolol HCl 20 mg tablet
0.36USD
tablet
Propranolol 20 mg tablet
0.33USD
tablet
Apo-Propranolol 120 mg Tablet
0.32USD
tablet
Propranolol HCl 10 mg tablet
0.29USD
tablet
Propranolol 10 mg tablet
0.22USD
tablet
Propranolol HCl 20 mg/5ml Solution
0.11USD
ml
Apo-Propranolol 80 mg Tablet
0.06USD
tablet
Novo-Pranol 80 mg Tablet
0.06USD
tablet
Pms-Propranolol 80 mg Tablet
0.06USD
tablet
Apo-Propranolol 20 mg Tablet
0.04USD
tablet
Apo-Propranolol 40 mg Tablet
0.04USD
tablet
Novo-Pranol 20 mg Tablet
0.04USD
tablet
Novo-Pranol 40 mg Tablet
0.04USD
tablet
Apo-Propranolol 10 mg Tablet
0.02USD
tablet
Novo-Pranol 10 mg Tablet
0.02USD
tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

### State

Solid

### Experimental Properties

Property
Value
Source
melting point (°C)
96 °C
PhysProp
water solubility
61.7 mg/L (at 25 °C)
MCFARLAND,JW ET AL. (2001)
logP
3.48
AVDEEF,A (1997)
Caco2 permeability
-4.58
ADME Research, USCD
pKa
9.42
SANGSTER (1994)

### Predicted Properties

Property
Value
Source
Water Solubility
0.0794 mg/mL
ALOGPS
logP
3.03
ALOGPS
logP
2.58
Chemaxon
logS
-3.5
ALOGPS
pKa (Strongest Acidic)
14.09
Chemaxon
pKa (Strongest Basic)
9.67
Chemaxon
Physiological Charge
1
Chemaxon
Hydrogen Acceptor Count
3
Chemaxon
Hydrogen Donor Count
2
Chemaxon
Polar Surface Area
41.49 Å
2
Chemaxon
Rotatable Bond Count
6
Chemaxon
Refractivity
76.83 m
3
·mol
-1
Chemaxon
Polarizability
29.98 Å
3
Chemaxon
Number of Rings
2
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
Yes
Chemaxon
Veber's Rule
No
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
0.9944
Blood Brain Barrier
-
0.9031
Caco-2 permeable
+
0.6942
P-glycoprotein substrate
Substrate
0.7079
P-glycoprotein inhibitor I
Inhibitor
0.5588
P-glycoprotein inhibitor II
Non-inhibitor
0.8383
Renal organic cation transporter
Non-inhibitor
0.8177
CYP450 2C9 substrate
Non-substrate
0.7898
CYP450 2D6 substrate
Substrate
0.8918
CYP450 3A4 substrate
Non-substrate
0.6463
CYP450 1A2 substrate
Inhibitor
0.9106
CYP450 2C9 inhibitor
Non-inhibitor
0.9071
CYP450 2D6 inhibitor
Inhibitor
0.8932
CYP450 2C19 inhibitor
Non-inhibitor
0.9026
CYP450 3A4 inhibitor
Non-inhibitor
0.924
CYP450 inhibitory promiscuity
Low CYP Inhibitory Promiscuity
0.8487
Ames test
Non AMES toxic
0.9392
Carcinogenicity
Non-carcinogens
0.9097
Biodegradation
Not ready biodegradable
0.9871
Rat acute toxicity
2.5625 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.9185
hERG inhibition (predictor II)
Inhibitor
0.7092
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
172.4736556
predicted
DarkChem Lite v0.1.0
[M-H]-
156.65192
predicted
DeepCCS 1.0 (2019)
[M+H]+
172.1881556
predicted
DarkChem Lite v0.1.0
[M+H]+
159.00992
predicted
DeepCCS 1.0 (2019)
[M+Na]+
172.1445556
predicted
DarkChem Lite v0.1.0
[M+Na]+
165.10306
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Humans

### Pharmacological action

Unknown

### Actions

Substrate

### General Function

Translocates drugs and phospholipids across the membrane (PubMed:2897240, PubMed:35970996, PubMed:8898203, PubMed:9038218, PubMed:35507548). Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins (PubMed:8898203). Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells (PubMed:2897240, PubMed:35970996, PubMed:9038218)

### Specific Function

ABC-type xenobiotic transporter activity

### Gene Name

ABCB1

### Uniprot ID

P08183

### Uniprot Name

ATP-dependent translocase ABCB1

### Molecular Weight

141477.255 Da

`,
  "protestkit": `{
  "url": "https://drugs.tripsit.me/propranolol",
  "experiencesUrl": "https://www.reddit.com/search/?q=Propranolol",
  "name": "Propranolol",
  "aliases": [
    "hemangeol",
    "inderal",
    "innopran"
  ],
  "aliasesStr": "hemangeol,inderal,innopran",
  "summary": "Is a nonselective beta blocker. It is used in medication for high blood pressure, anxiety, and tremors. Also fun fact, it was the first successful beta-blocker developed.",
  "reagents": null,
  "classes": {
    "chemical": [],
    "psychoactive": []
  },
  "toxicity": null,
  "addictionPotential": null,
  "tolerance": null,
  "crossTolerances": null,
  "roas": [
    {
      "name": "Oral",
      "dosage": [
        {
          "name": "Light",
          "value": "10-30mg"
        },
        {
          "name": "Common",
          "value": "40-80mg"
        },
        {
          "name": "Strong",
          "value": "80-140mg."
        }
      ],
      "duration": [
        {
          "name": "Onset",
          "value": "0.17 - 0.75 hours"
        },
        {
          "name": "Duration",
          "value": "3.0 - 7.0 hours"
        },
        {
          "name": "After effects",
          "value": "1.0 - 8.0 hours"
        }
      ]
    }
  ],
  "interactions": null,
  "effects": null,
  "categorized_effects": {
    "Physical effects": [],
    "Mental effects": [],
    "Sensory effects": [],
    "Uncategorized effects": []
  }
}`,
  "tripsit-factsheets": `# Propranolol
*Source: TripSit Factsheets (tripsit.me)*

## Summary

The drug is a nonselective beta blocker. It is used in medication for high blood pressure, anxiety, and tremors.

## Classification
- **Categories:** depressant, common
- **Also known as:** inderal, hemangeol, innopran

## Dosage

### Oral
- **Common:** 40-80mg
- **Light:** 10-30mg
- **Strong:** 80-140mg.

## Duration
- **Onset:** 10-45 minutes
- **Duration:** 3-7 hours
- **After Effects:** 1-8 hours

## Additional Information
- **Avoid:** All other CNS depressants.
`,
  "wikipedia": `# Propranolol
*Source: https://en.wikipedia.org/wiki/Propranolol*

Propranolol is a medication of the beta blocker class. It is used to treat high blood pressure, some types of irregular heart rate, thyrotoxicosis, capillary hemangiomas, akathisia, performance anxiety, and essential tremors, as well as to prevent migraine headaches, and to prevent further heart problems in those with angina or previous heart attacks. It can be taken orally, rectally, or by intravenous injection. The formulation that is taken orally comes in short-acting and long-acting versions. Propranolol appears in the blood after 30 minutes and has a maximum effect between 60 and 90 minutes when taken orally.
Common side effects include nausea, abdominal pain, and constipation. It may worsen the symptoms of asthma. Propranolol may cause harmful effects for the baby if taken during pregnancy; however, its use during breastfeeding is generally considered to be safe. It is a non-selective beta blocker which works by blocking β-adrenergic receptors.
Propranolol was patented in 1962 and approved for medical use in 1964. It is on the World Health Organization's List of Essential Medicines. Propranolol is available as a generic medication. In 2023, it was the 69th most commonly prescribed medication in the United States, with more than 9 million prescriptions.

## Medical uses

Propranolol is used for treating various conditions, including:

### Cardiovascular

Hypertension (high blood pressure)
Angina pectoris (with the exception of variant angina)
Myocardial infarction
Tachycardia (and other sympathetic nervous system symptoms, such as muscle tremor) associated with various conditions, including anxiety, panic, hyperthyroidism, and lithium therapy
Portal hypertension, to lower portal vein pressure
Prevention of esophageal variceal bleeding and ascites
Anxiety
Hypertrophic cardiomyopathy
While once a first-line treatment for hypertension, the role of beta blockers was downgraded in June 2006 in the United Kingdom to fourth-line, as they do not perform as well as other drugs, particularly in the elderly, and evidence is increasing that the most frequently used beta blockers at usual doses carry an unacceptable risk of provoking type 2 diabetes.
Propranolol is not recommended for the treatment of high blood pressure by the Eighth Joint National Committee (JNC 8) because a higher rate of the primary composite outcome of cardiovascular death, myocardial infarction, or stroke compared to an angiotensin receptor blocker was noted in one study.

### Anxiety and related disorders

Propranolol is occasionally used to treat performance anxiety, although evidence to support its use in any anxiety disorders is poor. Its efficacy in managing panic disorder appears similar to benzodiazepines, while carrying lower risks for addiction or abuse. Although beta-blockers such as propranolol have been suggested to be beneficial in managing physical symptoms of anxiety, its efficacy in treating generalized anxiety disorder and panic disorder remain unestablished. It is thought that beta blockers do not directly treat psychological symptoms of anxiety, but can help control physical symptoms such as palpitations, and this may interfere with a positive feedback loop to indirectly reduce psychological anxiety.
A 2025 systematic review and meta-analysis found widespread prescription of beta blockers, namely propranolol, for treatment of anxiety disorders, but found no evidence of a beneficial effect relative to placebo or benzodiazepines in people with social phobia or panic disorder. However, the quality of evidence, including both numbers of studies and patients as well as quality and risk of bias of those studies, was limited. Findings were similar in a previous 2016 systematic review and meta-analysis.
Other beta blockers that have been used to treat anxiety disorders besides propranolol include atenolol, betaxolol, nadolol, oxprenolol, and pindolol.
Some experimentation has been conducted in other psychiatric areas:

Post-traumatic stress disorder (PTSD) and specific phobias
Aggressive behavior of patients with brain injuries
Treating the excessive drinking of fluids in psychogenic polydipsia

#### Post-traumatic stress disorder and phobias

Propranolol is being investigated as a potential treatment for PTSD. Propranolol works to inhibit the actions of norepinephrine (noradrenaline), a neurotransmitter that enhances memory consolidation. In one small study, individuals given propranolol immediately after trauma experienced fewer stress-related symptoms and lower rates of PTSD than respective control groups who did not receive the drug. Due to the fact that memories and their emotional content are reconsolidated in the hours after they are recalled or re-experienced, propranolol can also diminish the emotional impact of already formed memories; for this reason, it is also being studied in the treatment of specific phobias, such as arachnophobia, dental fear, and social phobia. It has also been found to be helpful for some individuals with misophonia.
Ethical and legal questions have been raised surrounding the use of propranolol-based medications for use as a "memory damper", including altering memory-recalled evidence during an investigation, modifying the behavioral response to past (albeit traumatic) experiences, the regulation of these drugs, and others. However, Hall and Carter have argued that many such objections are "based on wildly exaggerated and unrealistic scenarios that ignore the limited action of propranolol in affecting memory, underplay the debilitating impact that PTSD has on those who suffer from it, and fail to acknowledge the extent to which drugs like alcohol are already used for this purpose".

### Other uses

Essential tremor. However, evidence for use for akathisia is insufficient.
Migraine and cluster headache prevention and in primary exertional headache
Hyperhidrosis (excessive sweating)
Infantile hemangioma
Glaucoma
Thyrotoxicosis by deiodinase inhibition
Propranolol may be used to treat severe infantile hemangiomas (IHs). This treatment shows promise as being superior to corticosteroids when treating IHs. Extensive clinical case evidence and a small controlled trial support its efficacy.
Propranolol is useful in the treatment of acute cardiovascular toxicity (e.g. in overdose) caused by sympathomimetics like amphetamine, methamphetamine, cocaine, ephedrine, and pseudoephedrine, including reducing elevations in heart rate and blood pressure caused by these agents. Other beta blockers are also used. However, the controversial yet possible phenomenon of "unopposed α-stimulation" with administration of selective beta blockers to block non-selective sympathomimetics potentially makes dual alpha-1 and beta blockers like labetalol and carvedilol more favorable for such purposes than selective beta blockers like propranolol. The rate of unopposed α-stimulation with selective beta blockers has been reported to be 0.4%, whereas no cases of unopposed α-stimulation have been reported with dual alpha and beta blockers like labetalol.

### Available forms

Propranolol is available in the form of 10, 20, 40, 60, and 80 mg (as propranolol hydrochloride) oral tablets, among other formulations.

## Contraindications

Contraindications of propranolol include cardiogenic shock, sinus bradycardia (slow heart rate; <60 beats/minute), heart block greater than first degree, bronchial asthma, overt heart failure, and known hypersensitivity to propranolol. Other contraindications include reversible airway diseases, particularly asthma or chronic obstructive pulmonary disease (COPD), sick sinus syndrome, atrioventricular block (second- or third-degree), circulatory shock, and severe hypotension (low blood pressure).
Propranolol should be used with caution in people with:

Diabetes mellitus or hyperthyroidism, since signs and symptoms of hypoglycemia may be masked
Peripheral artery disease and Raynaud syndrome, which may be exacerbated
Phaeochromocytoma, as hypertension may be aggravated without prior alpha blocker therapy
Myasthenia gravis, which may be worsened
Other drugs with bradycardic effects

## Side effects

### Pregnancy and lactation

Propranolol, like other beta-blockers, is classified as pregnancy category C in the United States and ADEC category C in Australia. β-blocking agents in general reduce perfusion of the placenta, which may lead to adverse outcomes for the neonate, including lung or heart complications, or premature birth. The newborn may experience additional adverse effects such as low blood sugar and a slower than normal heart rate.
Most β-blocking agents appear in the milk of lactating women. However, propranolol is highly bound to proteins in the bloodstream and is distributed into breast milk at very low levels. These low levels are not expected to pose any risk to the breastfeeding infant, and the American Academy of Pediatrics considers propranolol therapy "generally compatible with breastfeeding."

## Overdose

Propranolol overdose has been associated with symptoms including bradycardia and hypotension. These symptoms may be managed by drugs including glucagon, isoprenaline (isoproterenol), medication, phosphodiesterase inhibitors, or atropine, whereas epinephrine may provoke uncontrolled hypertension due to unopposed alpha stimulation and is not indicated. Propranolol overdose has also been associated with seizures. Cardiac arrest may occur in propranolol overdose due to sudden ventricular arrhythmias, or cardiogenic shock which may ultimately culminate in bradycardic PEA.

## Interactions

### Pharmacodynamic interactions

Since beta blockers are known to relax the cardiac muscle and constrict the smooth muscle, they have an additive effect with other drugs that decrease blood pressure or decrease cardiac contractility or conductivity. Pharmacodynamic interactions may occur with other drugs affecting the cardiovascular system, including propafenone, quinidine, amiodarone, cardiac glycosides, calcium channel blockers like verapamil and diltiazem, ACE inhibitors, alpha blockers like prazosin, catecholamine-depleting drugs like reserpine, ergot alkaloids, and adrenergic receptor agonists including epinephrine (adrenaline), isoprenaline (isoproterenol), dobutamine, β2-adrenergic receptor agonists like salbutamol, levosalbutamol, formoterol, salmeterol, and clenbuterol, and α2-adrenergic receptor agonists like clonidine. Tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) have hypotensive side effects and these may be exacerbated by propranolol. Hypotension and cardiac arrest have been reported with the combination of propranolol and haloperidol. Nonsteroidal anti-inflammatory drugs (NSAIDs), which include drugs like ibuprofen, naproxen, and aspirin, have been reported to blunt the antihypertensive effects of beta blockers like propranolol. The NSAID indomethacin specifically may reduce the efficacy of propranolol in decreasing heart rate and blood pressure.

### Effects of drugs on propranolol

Propranolol is metabolized by cytochrome P450 enzymes including CYP2D6, CYP1A2, and CYP2C19. Levels of propranolol may be increased by CYP2D6 inhibitors such as amiodarone, bupropion, cimetidine, duloxetine, fluoxetine, paroxetine, propafenone, quinidine, and ritonavir, by CYP1A2 inhibitors such as imipramine, cimetidine, ciprofloxacin, fluvoxamine, isoniazid, theophylline, zileuton, zolmitriptan, and rizatriptan, and by CYP2C19 inhibitors such as fluconazole, cimetidine, fluoxetine, fluvoxamine, teniposide, and tolbutamide. No interactions with propranolol were observed with ranitidine, lansoprazole, or omeprazole. Propranolol levels may be reduced by inducers of hepatic metabolism including rifampin, alcohol, phenytoin, phenobarbital, and cigarette smoking.
The CYP2D6 inhibitor quinidine has been found to increase propranolol levels by 2- to 3-fold. The CYP1A2 inhibitor fluvoxamine has been found to increase propranolol levels by 5-fold. The calcium channel blocker nisoldipine increased peak levels of propranolol by 1.5-fold and area-under-the-curve levels by 1.3-fold, while nicardipine increased propranolol peak levels by 1.8-fold and area-under-the-curve levels by 1.5-fold. Conversely, verapamil does not affect the pharmacokinetics of propranolol and vice-versa. The CYP1A2 inhibitor zolmitriptan increased peak propranolol levels by 1.4-fold and area-under-the-curve levels by 1.56-fold, while the CYP1A2 inhibitor rizatriptan increased propranolol peak levels by 1.8-fold and area-under-the-curve levels by 1.7-fold. Chlorpromazine has been found to increase propranolol levels by 1.7-fold. The non-selective CYP450 inhibitor cimetidine has been found to increase peak propranolol levels by 1.4-fold and area-under-the-curve levels by 1.5-fold. Cigarette smoking, which induces CYP1A2, has been found to reduce the clearance of propranolol by 77%, in turn resulting in decreased propranolol concentrations. The lipid-lowering drug cholestyramine or colestipol decreased propranolol levels by up to 50%. Aluminum hydroxide gel may decrease propranolol levels. Alcohol may increase propranolol levels.

### Effects of propranolol on other drugs

Propranolol has been found to increase area-under-the-curve levels of propafenone by more than 3-fold. It has been found to increase lidocaine levels by 1.3-fold. The drug has been found to increase peak and area-under-the-curve levels of nifedipine by 1.6-fold and 1.8-fold, respectively. Propranolol decreases theophylline clearance by 30 to 52%. Propranolol inhibits the metabolism of the benzodiazepine diazepam and can increase exposure to diazepam. Conversely, propranolol does not affect various other benzodiazepines, including oxazepam, triazolam, lorazepam, and alprazolam. High-dose long-acting propranolol has been found to increase thioridazine levels by 1.6- to 4.7-fold and levels of its metabolite mesoridazine by 1.3- to 3.1-fold. Propranolol decreased lovastatin or pravastatin area-under-the-curve levels by 18 to 23% but did not affect fluvastatin. It may decrease triiodothyronine (T3) levels when taken with thyroxine (T4). Propranolol has been found to increase the bioavailability and effects of warfarin.

## Pharmacology

### Pharmacodynamics

Propranolol is classified as a competitive non-cardioselective sympatholytic beta blocker that crosses the blood–brain barrier. It is lipid soluble and also has sodium channel-blocking effects. Propranolol is a non-selective β-adrenergic receptor antagonist, or beta blocker; that is, it blocks the action of epinephrine (adrenaline) and norepinephrine (noradrenaline) at both β1- and β2-adrenergic receptors. It has little intrinsic sympathomimetic activity, but has strong membrane stabilizing activity (only at high blood concentrations, e.g. overdose). Propranolol can cross the blood–brain barrier and exert effects in the central nervous system in addition to its peripheral activity.
In addition to blockade of adrenergic receptors, propranolol has very weak inhibitory effects on the norepinephrine transporter and/or weakly stimulates norepinephrine release (i.e., the concentration of norepinephrine is increased in the synapse). Since propranolol blocks β-adrenoceptors, the increase in synaptic norepinephrine only results in α-adrenoceptor activation, with the α1-adrenoceptor being particularly important for effects observed in animal models. Therefore, it can be looked upon as a weak indirect α1-adrenoceptor agonist in addition to potent β-adrenoceptor antagonist. In addition to its effects on the adrenergic system, there is evidence that indicates that propranolol may act as a relatively weak antagonist of certain serotonin receptors, namely the 5-HT1A, 5-HT1B, and 5-HT2B receptors. The latter may be involved in the effectiveness of propranolol in the treatment of migraine at high doses. (–)-Propranolol is not a silent antagonist of the serotonin 5-HT1A receptor but is instead a very weak partial agonist of the receptor.
Both enantiomers of propranolol have a local anesthetic (topical) effect, which is normally mediated by blockade of voltage-gated sodium channels. Studies have demonstrated propranolol's ability to block cardiac, neuronal, and skeletal voltage-gated sodium channels, accounting for its known membrane stabilizing effect and antiarrhythmic and other central nervous system effects.

#### Mechanism of action

Propranolol is a non-selective beta receptor antagonist. This means that it does not have preference to β1 or β2 receptors. It competes with sympathomimetic neurotransmitters for binding to receptors, which inhibits sympathetic stimulation of the heart. Blockage of neurotransmitter binding to β1 receptors on cardiac myocytes inhibits activation of adenylate cyclase, which in turn inhibits cAMP synthesis leading to reduced Protein kinase A (PKA) activation. This results in less calcium influx to cardiac myocytes through voltage-gated L-type calcium channels, meaning there is a decreased sympathetic effect on cardiac cells, resulting in antihypertensive effects including reduced heart rate and lower arterial blood pressure. Blocking neurotransmitter activity at β2 receptors in vascular smooth muscle cells causes vasoconstriction, leading to hypertension.

### Pharmacokinetics

#### Absorption

Propranolol is rapidly and completely absorbed, with peak plasma levels achieved about 2 hours (range 1–3 hours) after ingestion. Its oral bioavailability is approximately 25%. Despite complete absorption, propranolol has a variable bioavailability due to extensive first-pass metabolism. Hepatic impairment therefore increases its bioavailability. Effective plasma concentrations are between 10 and 100 mg/L. Toxic levels are associated with plasma concentrations above 2,000 mg/L. Coadministration with food appears to enhance bioavailability but does not hasten its time to peak levels. Propranolol can be absorbed along the whole intestine with the main absorption site being the colon, which means people who have lost their colon due to surgery may absorb less propranolol. Propranolol shows marked interindividual variability in pharmacokinetics, with propranolol levels varying 20-fold in different individuals.

#### Distribution

The volume of distribution of propranolol is about 4 L/kg or 320 L. The plasma protein binding of propranolol is approximately 90%, with a range of 85 to 96% in different studies. Propranolol is a highly lipophilic drug achieving high concentrations in the brain. The brain-to-blood ratio of propranolol in humans ranges from 15:1 to 33:1, whereas the ratio for the peripherally selective beta blocker atenolol has been found to be 0.2:1.

#### Metabolism

Propranolol undergoes metabolism via aromatic hydroxylation (mainly 4-hydroxylation), N-dealkylation, side-chain oxidation, and glucuronidation. The metabolism of propranolol involves cytochrome P450 enzymes including CYP2D6, CYP1A2, and CYP2C19. CYP1A2 and CYP2D6 have a major role, while CYP2C19 and CYP3A4 have a minor role. The main metabolite 4-hydroxypropranolol, which has a longer elimination half-life than propranolol, is also pharmacologically active.

#### Elimination

Propranolol is eliminated in urine. Approximately 91% of an oral dose of propranolol is eliminated in urine as 12 metabolites. Only about 1 to 4% of propranolol is excreted unchanged in urine or feces.
The elimination half-life of propranolol ranges from 2.8 to 8 hours in different studies, with a typical half-life of around 4 hours. The duration of action of a single oral dose is longer than the half-life and may be up to 12 hours if the single dose is high enough (e.g., 80 mg).

### Pharmacogenomics

There were no significance differences in area-under-the-curve levels of propranolol in CYP2D6 poor metabolizers versus extensive metabolizers. However, area-under-the-curve propranolol levels were ~2.5-fold higher in Caucasian CYP2D6 poor metabolizers or Chinese people with a non-functional CYP2D6 gene. The contribution of CYP2D6 to the metabolism of propranolol is less than with metoprolol and is described as only "marginal".

## Chemistry

Propranolol is highly lipophilic. The experimental log P of propranolol is 3.0 to 3.48 and its predicted log P ranges from 2.20 to 3.10.

## History

Scottish scientist James W. Black developed propranolol in the 1960s. It was the first beta-blocker effectively used in the treatment of coronary artery disease and hypertension.
Newer, more cardio-selective beta blockers (such as bisoprolol, nebivolol, carvedilol, or metoprolol) are used preferentially in the treatment of hypertension.

## Society and culture

### Performance enhancement

In a 1987 study by the International Conference of Symphony and Opera Musicians, it was reported that 27% of interviewed members said they used beta blockers such as propranolol for musical performances. For about 10 to 16% of performers, their degree of stage fright is considered pathological. Propranolol is used by musicians, actors, and public speakers for its ability to treat anxiety symptoms activated by the sympathetic nervous system. It has also been used as a performance-enhancing drug in sports where high accuracy is required, including archery, shooting, golf, and snooker. In the 2008 Summer Olympics, 50-metre pistol silver medalist and 10-metre air pistol bronze medalist Kim Jong-su tested positive for propranolol and was stripped of his medals.

### Brand names

Propranolol was first marketed under the brand name Inderal, manufactured by ICI Pharmaceuticals (now AstraZeneca), in 1965. "Inderal" is a quasi-anagram of "Alderlin", the trade name of pronethalol (which propranolol replaced); both names are an homage to Alderley Park, the ICI headquarters where the drugs were first developed.
Propranolol is also marketed under brand names Avlocardyl, Deralin, Dociton, Inderalici, InnoPran XL, Indoblok, Sumial, Anaprilin, and Bedranol SR (Sandoz). In India, it is marketed under brand names such as Ciplar and Ciplar LA by Cipla. Hemangeol, a 4.28 mg/mL solution of propranolol, is indicated for the treatment of proliferating infantile hemangioma.
`,
};
